By Tony Fong

NEW YORK (GenomeWeb News) – Fresh off its announcement that it had licensed a panel of genes for breast cancer detection, NanoString Technologies is seeking to expand its profile by moving into the molecular diagnostics space.

In a recent interview on the sidelines of the JP Morgan Healthcare Conference in San Francisco, Brad Gray, president and CEO of NanoString, said that with its life science tools business on firm footing, the company is now embarking on efforts to build its diagnostics business.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.